Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (441-450 of 455) with videos related to

Pageof 46
Sort By:
Stroke|May 22, 2025
Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS TrialPhilip S Nash, Hakim-Moulay Dehbi, Norin Ahmed, et al.
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
The Lancet. Digital Health|November 15, 2023
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UKSharlene A Greenwood, Hannah M L Young, Juliet Briggs, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 24, 2025
A Core Outcome Set for Trials in CKD: Report of the Standardized Outcomes in Nephrology-Chronic Kidney Disease (SONG-CKD) Stakeholder WorkshopsAndrea Matus Gonzalez, Rosanna Cazzolli, Magdalena Madero, et al.
JAMA|June 4, 2026
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical TrialSunil V Badve, Vlado Perkovic, Vivekanand Jha, et al.
Lancet (London, England)|June 14, 2011
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialColin Baigent, Martin J Landray, Christina Reith, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney diseaseDan-Qin Sun, Giovanni Targher, Christopher D Byrne, et al.
Pageof 46

Showing results (441-450 of 455) with videos related to

Sort By:
Pageof 46
Stroke|May 22, 2025
Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS TrialPhilip S Nash, Hakim-Moulay Dehbi, Norin Ahmed, et al.
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
The Lancet. Digital Health|November 15, 2023
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UKSharlene A Greenwood, Hannah M L Young, Juliet Briggs, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 24, 2025
A Core Outcome Set for Trials in CKD: Report of the Standardized Outcomes in Nephrology-Chronic Kidney Disease (SONG-CKD) Stakeholder WorkshopsAndrea Matus Gonzalez, Rosanna Cazzolli, Magdalena Madero, et al.
JAMA|June 4, 2026
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical TrialSunil V Badve, Vlado Perkovic, Vivekanand Jha, et al.
Lancet (London, England)|June 14, 2011
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialColin Baigent, Martin J Landray, Christina Reith, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney diseaseDan-Qin Sun, Giovanni Targher, Christopher D Byrne, et al.
Pageof 46